| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_24947414f5fe0841edf3b3a8cf2017b2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7c36d1b71cfe3507555683a0c4b26da8 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2799-022 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-482
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-79
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0075 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B82Y5-00 |
| filingDate |
2012-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf8f4c44c17afa2a5ce58cd95506f372
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_23dadf4b8bc16a66290f6ecf999c7989
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f8675417ce8f424d1b7341fbd8cbbb9c |
| publicationDate |
2013-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2013129960-A1 |
| titleOfInvention |
Pharmaceutical composition producing human lactoferrin, method for producing said composition and treatment method |
| abstract |
The invention relates to the field of medicine and concerns a pharmaceutical composition in which the treatment effect is produced as a result of the action of the antioxidant, antimicrobial and antitoxic human lactoferrin protein and which comprises non-replicating nanoparticles based on the genome of human adenovirus serotype 5 with a human lactoferrin gene insert, said nanoparticles expressing human lactoferrin in an organism in an amount of not less than 2.33⋅10 11 physical particles per ml of buffer, and a formulating buffer. The method for producing the composition comprises inoculating a permissive cell culture with 293 non-replicating nanoparticles having the human lactoferrin gene, cultivating the culture, subjecting the latter to multi-stage purification and adding the formulating buffer. The treatment method comprises administering the composition in a therapeutically effective dose of 7⋅10 11 to 7⋅10 13 physical particles in a glucose solution to a person in two successive stages, twenty-four hours apart. |
| priorityDate |
2012-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |